Search

Your search keyword '"Migahid, Osama"' showing total 13 results
Start Over Author "Migahid, Osama"
13 results on '"Migahid, Osama"'

2. Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control

Author

Ponirakis, Georgios, primary, Abdul‐Ghani, Muhammad A, additional, Jayyousi, Amin, additional, Zirie, Mahmoud A, additional, Al‐Mohannadi, Salma, additional, Almuhannadi, Hamad, additional, Petropoulos, Ioannis N, additional, Khan, Adnan, additional, Gad, Hoda, additional, Migahid, Osama, additional, Megahed, Ayman, additional, Qazi, Murtaza, additional, AlMarri, Fatema, additional, Al‐Khayat, Fatima, additional, Mahfoud, Ziyad, additional, DeFronzo, Ralph, additional, and Malik, Rayaz A, additional

Published
2021
Full Text
View/download PDF

3. Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control

Author

Ponirakis, Georgios, primary, Abdul‐Ghani, Muhammad A, additional, Jayyousi, Amin, additional, Zirie, Mahmoud A, additional, Qazi, Murtaza, additional, Almuhannadi, Hamad, additional, Petropoulos, Ioannis N, additional, Khan, Adnan, additional, Gad, Hoda, additional, Migahid, Osama, additional, Megahed, Ayman, additional, Al‐Mohannadi, Salma, additional, AlMarri, Fatema, additional, Al‐Khayat, Fatima, additional, Mahfoud, Ziyad, additional, Al Hamad, Hanadi, additional, Ramadan, Marwan, additional, DeFronzo, Ralph, additional, and Malik, Rayaz A, additional

Published
2021
Full Text
View/download PDF

5. Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study

Author

Ponirakis, Georgios, primary, Abdul-Ghani, Muhammad A, additional, Jayyousi, Amin, additional, Almuhannadi, Hamad, additional, Petropoulos, Ioannis N, additional, Khan, Adnan, additional, Gad, Hoda, additional, Migahid, Osama, additional, Megahed, Ayman, additional, DeFronzo, Ralph, additional, Mahfoud, Ziyad, additional, Hassan, Mona, additional, Al Hamad, Hanadi, additional, Ramadan, Marwan, additional, Alam, Uazman, additional, and Malik, Rayaz A, additional

Published
2020
Full Text
View/download PDF

9. Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331

Author

Abdul-Ghani, Muhammad, primary, Migahid, Osama, additional, Megahed, Ayman, additional, Adams, John, additional, Triplitt, Curtis, additional, DeFronzo, Ralph A., additional, Zirie, Mahmoud, additional, and Jayyousi, Amin, additional

Published
2017
Full Text
View/download PDF

12. Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin‐treated T2DM patients: Results from the Qatar Study.

Author

Abdul‐Ghani, Muhammad, Migahid, Osama, Megahed, Ayman, Singh, Rajvir, Fawaz, Mohammad, DeFronzo, Ralph A., and Jayyousi, Amin

Subjects
*INSULIN resistance, *PIOGLITAZONE, *DAPAGLIFLOZIN, *BLOOD sugar, *HYPOGLYCEMIA, *TREATMENT of diabetes, *CLINICAL trials
Abstract

Because of the unique mechanism of action of sodium‐glucose co‐transport inhibitors (SGLT2i), which is independent of insulin secretion and insulin action, members of this class of drugs effectively lower plasma glucose concentration when used in combination with all other antidiabetic agents, including insulin. Increased plasma ketone concentration has been reported in association with SGLT2i initiation, which, under certain clinical conditions, has developed into diabetic ketoacidosis. The daily insulin dose often is reduced at the time of initiating SGLT2i therapy in insulin‐treated patients to avoid hypoglycaemia. However, reduction of insulin dose can increase the risk of ketoacidosis. In the present study, we examined the effect of the addition of dapagliflozin plus pioglitazone on plasma ketone concentration in insulin‐treated T2DM patients and compared the results to the effect of dapagliflozin alone. A total of 18 poorly controlled, insulin‐treated T2DM participants in the Qatar Study received dapagliflozin (10 mg) plus pioglitazone (30 mg), and 10 poorly controlled non‐insulin‐treated T2DM patients received dapagliflozin (10 mg) alone for 4 months. Dapagliflozin plus pioglitazone produced a robust decrease in HbA1c (−1.4%) and resulted in a 50% reduction in daily insulin dose, from 133 to 66 units, while dapagliflozin alone caused a 0.8% reduction in HbA1c. Dapagliflozin caused a four‐fold increase in fasting plasma ketone concentration, while the combination of pioglitazone plus dapagliflozin was not associated with a significant increase (0.13 vs 0.15 mM) in plasma ketone concentration or in risk of hypoglycaemia. These results demonstrate that the addition of pioglitazone to dapagliflozin prevents the increase in plasma ketone concentration associated with SGLT2i therapy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.

Author

Migahid, Osama, Megahed, Ayman, Kamal, Dalia, Jayyousi, Amin, Abdul‐Ghani, Muhammad, DeFronzo, Ralph A., and Singh, Rajvir

Subjects
*PANCREATIC beta cells, *EXENATIDE, *PIOGLITAZONE, *METFORMIN, *TYPE 2 diabetes treatment
Abstract

The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near‐maximum doses of metformin plus a sulfonylurea. Participants in the Qatar study received a 75‐g OGTT with measurement of plasma glucose, insulin and C‐peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year. Insulin secretion measured with plasma C‐peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c ≤ 7.0%) with pioglitazone plus exenatide. A 54% increase in 2‐hour plasma C‐peptide concentration above the fasting level identified subjects who achieved the glycaemic goal (HbA1c < 7.0%) with 82% sensitivity and 79% specificity. Only baseline HbA1c was a predictor of response to basal/bolus insulin therapy. Thus, the increment in 2‐hour plasma C‐peptide concentration above the fasting level provides a useful tool to identify poorly controlled T2DM patients who can achieve glycaemic control without insulin therapy, and thereby, can be used to individualize antihyperglycaemic therapy in poorly controlled T2DM patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results